Cardiovascular

FDA approves Corifact for congenital Factor XIII deficiency

The U.S. Food and Drug Administration has approved Corifact, the first product for preventing bleeding in people with congenital Factor XIII deficiency. Read more at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm243856.htm.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares